Klotho: The Longevity Protein With a Zero in the Human Column

The Protein Your Feed Says Your Doctor Is Hiding

The post had thirty-four thousand likes when it crossed my screen last week. "THE ANTI-AGING PROTEIN YOUR BODY ALREADY MAKES AND THE MODERN DIET IS DESTROYING," it shouted, in the all-caps register that should always make you reach for the original paper. "Most people have never heard of Klotho. Most doctors never mention it. Your levels are likely tanking."

Two of those three claims are wrong, and the third is half-right in a way that matters. So let's do what the post didn't: read the studies.

Klotho is real. It is not a supplement company invention or a wellness neologism. It was discovered in 1997 by a Japanese lab that disrupted a single mouse gene and accidentally built an animal that aged in fast-forward.¹ They named the gene after Klotho, the Greek Fate who spins the thread of human life. The protein has a serious pedigree in aging biology, and the people studying it are not cranks.

What's new is the marketing layer that has grown on top of the science like a second skin. Bryan Johnson, the entrepreneur who turned his own bloodstream into a content series, has reportedly paid for klotho gene therapy. A company called Klotho Neurosciences trades on the Nasdaq under the ticker KLTO. A clinic operating from a special economic zone in Honduras advertises a klotho gene-therapy package for around twenty-five thousand dollars, with "coming 2026" energy.^13,15 The premise everywhere is identical: science found the fountain of youth, your doctor isn't telling you, and a checkout button can fix that.

I want to be fair to klotho, because the animal data is genuinely some of the most interesting in the longevity field. But "interesting in mice" and "proven in humans you can buy today" are separated by a gap roughly the width of everything that matters in medicine. This issue is about that gap.

What Klotho Actually Does

Start with the part that's true. Klotho is a protein your body makes, mostly in the kidney, and its levels in the blood do fall with age. So the viral framing isn't conjured from nothing. The question is whether that decline causes aging, or merely accompanies it, the way grey hair accompanies birthdays without causing them.

There are two versions of the protein, and the distinction is the whole game. The membrane-bound form sits on kidney cells and acts as an obligatory co-receptor for a hormone called fibroblast growth factor 23, or FGF23, which governs how your body handles phosphate and vitamin D.⁹ That is not glamorous anti-aging work. It is mineral plumbing, and it is the reason klotho cannot be casually dialed up without consequences, a point the supplement crowd skips.

The form everyone gets excited about is the secreted version, sometimes written as s-klotho or alpha-klotho, which is cleaved off and circulates like a hormone. In the lab, this soluble form does things that look like rejuvenation. It appears to suppress insulin and IGF-1 signaling, the same pathway that, when turned down, extends lifespan in worms, flies, and mice.² The original 1997 mice told the story by negation: with the gene crippled, they developed arteriosclerosis, soft-tissue calcification, osteoporosis, skin and muscle wasting, and infertility, and they died at around two months old.¹

That experiment proves something narrow and important. Removing klotho accelerates a syndrome that resembles aging. It does not prove that adding extra klotho to an animal that already has enough will make it live longer or think more clearly. Those are different experiments, and the field has spent twenty-five years trying to run the second one. The results are where the hype starts to outrun its evidence.

Twenty Percent Longer — If You Happen to Be a Mouse

The headline numbers driving the current cycle are real, peer-reviewed, and almost entirely non-human. Here are the three studies doing the work.

I want to sit on that last point, because it's the one the influencers leave out. In the monkey study, more was not better. The dose that helped was the small one. The bigger doses produced nothing measurable.⁴ That is not a quirk; it echoes a human genetic finding we'll get to in a moment, and it is the opposite of how a supplement protocol wants the world to work.

What We Actually Know About People

Here is the entire human evidence base, and I mean entire. It is observational, it is genetic, and it contains exactly zero completed randomized trials showing that raising klotho extends life, sharpens cognition, or reverses aging in a person.

The most cited human work comes from Dena Dubal's group at UCSF. In 2014 they reported that people carrying one copy of a klotho gene variant called KL-VS, about one in five of us, had modestly higher klotho levels and performed slightly better on cognitive tests.⁵ Later work found the variant tracked with lower Alzheimer's risk, specifically in people who also carry the APOE4 risk gene.⁶ That sounds like a green light until you read the next sentence in the same body of research.

The other human thread is correlational blood-level work. Lower circulating klotho is associated with higher all-cause mortality in older adults.⁷ That is the data point the "your levels are tanking" posts lean on hardest, and it's the easiest one to misread. Low klotho travels with kidney disease, frailty, and chronic illness. The kidney is the main factory for the protein, and in chronic kidney disease klotho falls early, before phosphate and FGF23 climb.⁸ So low klotho may simply be a flare sent up by a failing organ, a marker of being sick rather than a cause of getting old. Association studies cannot tell those apart, and this one doesn't.

What about the "modern diet is destroying it" claim, the emotional core of the viral post? I could not find robust human evidence that any particular diet destroys klotho or that any supplement reliably raises it. The one lifestyle factor with real human data is exercise. A meta-analysis of twelve studies and 621 people found that twelve or more weeks of training modestly raised circulating klotho,¹⁰ and a 2026 review confirmed measurable acute and chronic exercise effects.¹¹ Which is a genuinely useful finding, and also a deflating one for the marketplace, because the intervention with the best human evidence for raising your klotho is the gym, and it's free.

Twenty-Five Thousand Dollars for Mouse Data

If the science stopped at "promising target, needs human trials," there would be no issue to write. What turns this from Insufficient Data into something closer to a warning is the commercial layer that has run several years ahead of the evidence.

At the consumer end are the supplements, pills branded with the klotho name or marketed to "boost" it, resting on cell-culture and rodent data with no human proof they raise the protein or change anything you'd care about. You also cannot meaningfully take klotho as an oral supplement; it is a large protein that your digestion would treat like any other dietary protein, breaking it into amino acids. Selling klotho in a capsule is a bit like selling insulin as a gummy.

At the expensive end is gene therapy. The Honduran clinic offering klotho and follistatin plasmid therapy operates outside FDA jurisdiction, charges about twenty-five thousand dollars, and has published no rigorous clinical trial data. Independent gene-therapy scientists interviewed about it have been blunt, calling the approach poorly conceived and noting the human evidence simply isn't there.¹³ This is real gene therapy with real, non-reversible risks, immune reactions and off-target effects among them, sold on the strength of mouse experiments.

That last one deserves a sentence on its own. The Nasdaq company built on this science holds an FDA Orphan Drug Designation for an ALS gene-therapy candidate, which is a development incentive and emphatically not an efficacy approval, and projects starting a Phase 1/2 trial no earlier than the second half of 2026.¹⁵ In March 2026 it completed a reverse merger with a Greenland mining outfit, leaving the mining stakeholders with the overwhelming majority of shares. I will let you decide what a longevity-biotech-turned-mining-vehicle tells you about where the value really sits. Where the science is loudest on social media, the financial incentives tend to be loudest too.

One more honesty note, because it cuts against my own skepticism. Klotho behaves as a tumor suppressor in several cancers, dampening the same growth-signaling pathways it quiets elsewhere.¹² That is usually cited as a benefit. But the biology is context-dependent and pleiotropic, and chronically forcing high systemic klotho through gene therapy has unknown long-term oncologic effects in humans, in either direction. "It suppresses tumors in a dish" is not a safety profile.

The Verdict